日本語 | English

Stem Cell

 

Practical Applications of iPS Cells

Stem cells and induced pluripotent stem cells (iPS or iPSCs) have found their usage in a large number of human welfare such as drug development, toxicity tests, organ/ tissue regeneration and repair etc. Induced pluripotent stem cells (iPSCs) could also be of great use in studying molecular mechanism of many diseases. Many diseases have been modeled by using iPSCs for better understanding of their etiology which maybe further utilized for developing putative treatments for these diseases. The use of iPSCs may eliminate the chances of immune rejection as patient specific cells may be used for transplantation in various engraftment processes.Moreover, iPS technology has been employed in various diseases for disease modeling and gene therapy. The technique offers benefits over other similar techniques such as animal models. Many toxic compounds (different chemical compounds, pharmaceutical drugs, other hazardous chemicals, or environmental conditions) which are encountered by humans and newly designed drugs may be evaluated for toxicity and effects by using iPSCs. The applications of stem cells and especially iPSCs in regenerative medicine, disease modeling, and drug discovery are enormous and should be explored in a more comprehensive manner.


In this web presentation you read 6 major applications of Stem cells and IPS cells:

  • Uses in Regenerative medicine (tissue/organ regeneration)
  • Uses in Disease modelling
  • Uses in Drug Discovery / Development
  • Uses in Drug testing/ Toxicity Testing
  • Uses in Tissue repair
  • Uses in Gene Therapy

Advantages of iPS technology over other conventional therapies:

  • The ethical issues are avoided by the use of iPSCs
    iPSCs have solved the controversy over the destruction of embryos associated with the use of ES Cells (embryonic stem cells).
  • Reduced chances of immunorejection
    iPSCs are generated from the somatic cells of one's own body and hence there is no risk of immunorejection of these autologous cells.
  • Throughput screening for predicting toxicity/therapeutic responses of newly developed drugs
    The concept of using iPSCs to predict toxicology and therapeutic responses of drugs in based on the property of iPSCs to continuously self- renew which make it possible to generate libraries and their ability to give rise to all types of body cells.
  • Lowering the overall cost and risk of clinical trials
    The cost used for the clinical trials could be reduced by using iPSCs to provide the toxicity details of the drug by different cytotoxicity assays. The use of iPSCs for these tests may cut the cost associated with providing animal models which will ultimately decrease the overall costs of the clinical trials.
  • Development of a personalized approach for administration of drugs
    As, iPSCs are derived from individual patients, these offer scientists an opportunity for modeling diseases on a patient-by-patient basis. This enables screening the genomic differences between individuals that may help in the progression of disease, and the screening of pharmacological agents to find the ideal one for each individual.
  • Gene targeting and correction technologies (gene therapy)
    Reprogramming of somatic cells from any genetic background to iPSCs has allowed the generation of cell lines possessing disease-causing mutations.

 


Copyright: No reproduction or republication without written permission.